

Pharmacoeconomic report, summary

Alitretinoin (Toctino®) for the indication preoperative treatment of severe chronic hand eczema.

Recommendation by CVZ dated 17-12-2012, based on an evaluation by the CFH (Medicinal Products Reimbursement Committee)

Summary

The Medicinal Products Reimbursement Committee (CFH) has approved a pharmacoeconomic report for the medicine alitretinoin (Toctino®). The CFH came to the following conclusions.

Economic evaluation

The economic evaluation was carried out via cost-utility analysis. A Markov model was used. The study results, measured over a period of 1 year, were extrapolated to a period of 3 years.

Comparative treatment

In the economic evaluation alitretinoin was compared with best supportive care.

Effects

The effects of treatments are expressed in quality-adjusted life-years (QALYs). The applicant reported a health expectation of 1.67 QALY per patient over a 3-year period as a result of using alitretinoin. The health gains in comparison with best supportive care over three years is 0.28 QALY per patient.

Costs

Direct medical costs, direct non-medical costs and indirect non-medical costs were included in the model. The average costs per patient treated with alitretinoin over 3 years were €17,411. The average incremental costs per patient were €1,308 in comparison with the costs of best supportive care.

Cost-effectiveness

The applicant reported an incremental cost-utility ratio (ICUR) of €4,654 per QALY in comparison with best supportive care.

Final conclusion

The applicant claims that treatment with alitretinoin is a cost-effective intervention for the treatment of severe chronic hand eczema.

The CG concludes that the cost-effectiveness of alitretinoin in the treatment of severe chronic hand eczema has been validly estimated and that the cost-effectiveness is reasonable.

*The original text of this excerpt from a **WAR-Report** of CVZ was in Dutch. Although great care was taken in translating the text from Dutch to English, the translation may nevertheless have resulted in discrepancies. Rights may only be derived on the basis of the Dutch version of CVZ's WAR-Report.*

Furthermore, CVZ points out that only the summary of this report was translated. A proper understanding of all relevant considerations and facts would require familiarity with the Dutch version of this report, including all appendices.